Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

NCT03802396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

203

Enrollment

OTHER

Sponsor class

Conditions

Postoperative Delirium
Postoperative Cognitive Dysfunction

Interventions

DRUG: CN-105
DRUG: Placebo

Sponsor

Miles Berger, MD PhD